Incyte (INCY) Competitors $68.59 -1.75 (-2.49%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$68.33 -0.26 (-0.37%) As of 07/11/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock INCY vs. ABBV, ALNY, BIIB, UTHR, NBIX, EXEL, BMRN, EXAS, RGEN, and HALOShould you be buying Incyte stock or one of its competitors? The main competitors of Incyte include AbbVie (ABBV), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Exelixis (EXEL), BioMarin Pharmaceutical (BMRN), Exact Sciences (EXAS), Repligen (RGEN), and Halozyme Therapeutics (HALO). These companies are all part of the "medical" sector. Incyte vs. Its Competitors AbbVie Alnylam Pharmaceuticals Biogen United Therapeutics Neurocrine Biosciences Exelixis BioMarin Pharmaceutical Exact Sciences Repligen Halozyme Therapeutics AbbVie (NYSE:ABBV) and Incyte (NASDAQ:INCY) are both large-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, dividends, profitability, valuation, earnings, risk and institutional ownership. Which has more volatility and risk, ABBV or INCY? AbbVie has a beta of 0.48, indicating that its share price is 52% less volatile than the S&P 500. Comparatively, Incyte has a beta of 0.68, indicating that its share price is 32% less volatile than the S&P 500. Which has higher earnings and valuation, ABBV or INCY? AbbVie has higher revenue and earnings than Incyte. AbbVie is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAbbVie$56.33B6.03$4.28B$2.3581.84Incyte$4.24B3.13$32.62M$0.32214.34 Do insiders and institutionals have more ownership in ABBV or INCY? 70.2% of AbbVie shares are held by institutional investors. Comparatively, 97.0% of Incyte shares are held by institutional investors. 0.3% of AbbVie shares are held by company insiders. Comparatively, 17.8% of Incyte shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the media favor ABBV or INCY? In the previous week, AbbVie had 89 more articles in the media than Incyte. MarketBeat recorded 110 mentions for AbbVie and 21 mentions for Incyte. AbbVie's average media sentiment score of 0.83 beat Incyte's score of 0.74 indicating that AbbVie is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AbbVie 71 Very Positive mention(s) 4 Positive mention(s) 16 Neutral mention(s) 4 Negative mention(s) 3 Very Negative mention(s) Positive Incyte 11 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is ABBV or INCY more profitable? AbbVie has a net margin of 7.31% compared to Incyte's net margin of 0.48%. AbbVie's return on equity of 412.03% beat Incyte's return on equity.Company Net Margins Return on Equity Return on Assets AbbVie7.31% 412.03% 13.11% Incyte 0.48%2.77%1.77% Do analysts recommend ABBV or INCY? AbbVie presently has a consensus price target of $211.29, indicating a potential upside of 9.86%. Incyte has a consensus price target of $74.53, indicating a potential upside of 8.67%. Given AbbVie's stronger consensus rating and higher possible upside, equities analysts clearly believe AbbVie is more favorable than Incyte.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AbbVie 0 Sell rating(s) 8 Hold rating(s) 16 Buy rating(s) 3 Strong Buy rating(s) 2.81Incyte 1 Sell rating(s) 12 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.22 SummaryAbbVie beats Incyte on 13 of the 17 factors compared between the two stocks. Get Incyte News Delivered to You Automatically Sign up to receive the latest news and ratings for INCY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding INCY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INCY vs. The Competition Export to ExcelMetricIncyteMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$13.28B$2.94B$5.56B$9.11BDividend YieldN/A2.42%5.06%4.01%P/E Ratio214.3520.8528.2620.26Price / Sales3.13303.05437.10166.10Price / Cash123.9042.1137.1257.67Price / Book3.837.638.045.49Net Income$32.62M-$55.05M$3.19B$250.45M7 Day Performance0.19%8.43%3.62%4.79%1 Month Performance1.24%8.14%5.98%9.59%1 Year Performance7.74%1.62%29.39%16.41% Incyte Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INCYIncyte4.7329 of 5 stars$68.59-2.5%$74.53+8.7%+7.7%$13.28B$4.24B214.352,617ABBVAbbVie4.5022 of 5 stars$187.44-1.0%$211.29+12.7%+12.9%$331.09B$56.33B79.7655,000Trending NewsAnalyst RevisionALNYAlnylam Pharmaceuticals4.1824 of 5 stars$324.13-2.3%$341.91+5.5%+20.9%$42.26B$2.25B-155.092,230Positive NewsAnalyst ForecastBIIBBiogen4.7786 of 5 stars$130.13-2.1%$188.48+44.8%-41.7%$19.07B$9.68B12.857,605Trending NewsAnalyst RevisionUTHRUnited Therapeutics4.9887 of 5 stars$290.39-1.4%$386.15+33.0%-8.0%$13.10B$2.88B11.591,305News CoveragePositive NewsAnalyst ForecastNBIXNeurocrine Biosciences4.5451 of 5 stars$127.88-1.0%$162.00+26.7%-9.5%$12.66B$2.36B43.351,800Trending NewsAnalyst ForecastInsider TradeAnalyst RevisionEXELExelixis4.7886 of 5 stars$44.16-4.3%$43.56-1.4%+100.3%$12.04B$2.17B20.071,147Analyst ForecastBMRNBioMarin Pharmaceutical4.9453 of 5 stars$57.41-0.2%$93.61+63.1%-31.7%$11.01B$2.85B21.343,040News CoveragePositive NewsEXASExact Sciences4.7669 of 5 stars$52.48-1.6%$70.40+34.1%+12.0%$9.90B$2.76B-9.527,000News CoverageAnalyst ForecastRGENRepligen4.6023 of 5 stars$124.43-2.4%$172.83+38.9%+3.4%$6.99B$634.44M-276.511,778Positive NewsAnalyst ForecastHALOHalozyme Therapeutics4.8246 of 5 stars$54.22+0.4%$61.90+14.2%+7.5%$6.68B$1.02B14.42390News CoverageAnalyst ForecastInsider Trade Related Companies and Tools Related Companies AbbVie Competitors Alnylam Pharmaceuticals Competitors Biogen Competitors United Therapeutics Competitors Neurocrine Biosciences Competitors Exelixis Competitors BioMarin Pharmaceutical Competitors Exact Sciences Competitors Repligen Competitors Halozyme Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INCY) was last updated on 7/13/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Incyte Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Incyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free INCY Stock Alerts